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Surprises, Optimism, MalaiseOverseeing eight-digit cash allotments
and making decisions that could radically
impact the direction of stem cell science
were some of the tough tasks expected
of Alan Trounson during his 6.5 years as
President of the California Institute for
Regenerative Medicine, a position he
stepped down from last May.
He had one easy job, however, which
was compiling a list of research highlights
for the monthly blog he wrote with Don
Gibbons, CIRM’s Senior Science Com-
munications Officer. ‘‘I never had a prob-
lem finding papers that astonished me,’’
says Trounson, who recalls that shortly
after he began at CIRM on the last day
of 2007, ‘‘the field started opening like a
big flower.’’ The evidence from Salk Insti-
tute that cell signaling in the neurons of
schizophrenics differs from the same ac-
tivity in nonschizophrenics; the Stanford
report that some of the genes that control
cancer growth in humans are the same
genes that control limb growth in sala-
manders; the remarkable ability of spe-
cific transcription factors to reprogram
cardiac fibroblasts to functional cardio-
myocytes in vivo, at the Gladstone Insti-
tutes, were all examples. ‘‘On and on—
findings kept happening that no one could
have foreseen.’’
Surprises became a leitmotif of sorts.
Trounson believes that CIRM is building
a strong science base not only for regen-
erative medicine but also for autism,
schizophrenia, and mental retardation,
‘‘which I wouldn’t have expected. And I
never thought we’d create a potential
cure for HIV/AIDS that could allow pa-
tients who are on protease inhibitors to
go off their meds and be free of the
disease.’’ A CIRM-backed clinical trial, in
which a patient’s blood-forming stem
cells, when genetically altered, make
T cells that are resistant to the virus, is
the first chimeric antigen receptor type
treatment of its kind being attempted
anywhere in the world. Trounson has a
brother with AIDS. ‘‘In a world of diminish-
ing effective antibiotics, this approach to
target specifically infected cells may be
the way forward to arm us against deadly
infections,’’ Trounson believes.The idea that stem cell science might
impact disorders like autism and mental
illness arose from another unanticipated
advance, namely the ability to obtain
induced pluripotent stem cells (iPSCs)
from human skin cells in 2007. Last year,
CIRM invested $32 million in an iPSC
repository that might eventually house
9,000 cell lines made from patients’
iPSCs. Eleven multigenetic diseases will
come under scrutiny. For these inves-
tigations to flourish, says Trounson,
numerous challenges await, starting with
‘‘the recognition that iPSCs made from
patient populations of disease conditions,
or susceptibility to infection of disease,
represents the heterogeneity of the hu-
man condition, rather than the rodent
animal models currently used. The de-
signs of iPS disease-in-the-dish models
are progressing, and these may be used
for discovery of the underlying aberrant
gene pathways that constitute the
pathological phenotype of the disease.
From there we need to construct high-
throughput screens to identify new candi-
date drugs that effectively prevent or
reverse the disease phenotype. These
iPSCs are an incredible resource for sci-
entists and companies.’’
A little over 1 year after Trounson arrived
at CIRM, he and his staff found their
mission billowed forward by something
else that had been impossible to foresee:
President Obama’s 2009 lifting of restric-
tions on human embryonic stem cell
(ESC) lines that George W. Bush had put
in place 8 years earlier. Since Obama’s
election had been a long shot, CIRM had
had to create 12 new institutes and a large
number of common laboratories to get
around the problem of comingling federal
and state funds. On March 9, 2009, the
day of Obama’s announcement, cham-
pagne flowed inside CIRM’s San Fran-
cisco offices on King Street, along with
optimism (Figure 1). Obama’s affirmation
of the research ‘‘dramatically raised
morale across the country, especially in
California, because it was a very strong
endorsement of Proposition 71,’’ the law
that established CIRM on the back of
bond sales, remembers Trounson.Cell Stem Cell 1Researchers went from having fewer
than 20 viable human ESC lines available
for federally funded research to hundreds
today. The new ability to create ESC-like
lines from iPSCs has further increased
the supply, to the point where Trounson,
a pioneer of in vitro fertilization and tech-
niques for freezing embryos, feels that,
‘‘it shouldn’t be necessary to make large
numbers of new lines.’’ Don Gibbons
notes, ‘‘You need a very compelling
reason these days to derive a new ESC
line’’ from an IVF embryo. ‘‘It’s done very
sparingly. We frequently receive calls
from couples wanting to donate embryos
to research, and we try to find them a lab
accepting donationsbut can’t always suc-
ceed. Many of the new lines being made
are to improve racial diversity among the
lines or to gain genetic disease models.’’
Once the Bush ban was overturned, ‘‘it
was disappointing’’ for the field that,
owing to the economy, ‘‘more federal
funds didn’t follow,’’ notes Trounson.
CIRM subsists on state, not federal,
funds, and was not too disadvantaged.
He recounts what a privilege it was ‘‘to
have worked with a large amount of
money and a great group of people, and
to have driven what inmymind represents
a revolution in medicine and science.’’
During his presidency, grants approved
by CIRM’s board went from 156 to over
640. Funds awarded went from $236
million to approximately $1.86 billion of
the agency’s total allotted funds of $3
billion. ‘‘I really wanted the best scientists
in California to be working with the best
scientists in the world,’’ and Trounson
feels he accomplished the goal of the
agency being ‘‘more networked at all
different levels.’’ Thirty collaborations are
now in place, twenty-two of which are
international in reach. Outside partners
pay for their side of the research, and to
date they have contributed approximately
$80 million.
Nothing is more essential to scientific
progress than creativity, and nothing
quickens creativity like collaboration,
Trounson wholeheartedly believes. ‘‘Link-
ing people up with different approaches
gives you a fresh look at a problem and5, October 2, 2014 ª2014 Elsevier Inc. 403
Figure 1. A Reproduction of President Obama’s March 2009
Proclamation, Signed by CIRMEmployees, Hangs in CIRM’s Kitchen
in San Francisco
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eries you wouldn’t otherwise
make.’’ He says he’s seen a
lot of ‘‘silliness’’ in labs where
people are too protective of
their data and don’t collabo-
rate and progress is slow.
Diverse partnerships were
a catalyst for Trounson’s sec-
ond goal for CIRM, to be
‘‘more clinically oriented.’’
(‘‘Universities are not tradi-
tionally involved in transla-
tional research and don’t
provide recognition for this
demanding work, whereas
companies can be too reliant
onscarcecontinuedfinancing
at multiple milestones,’’ re-
sulting in research work that
isn’t sustainable. ‘‘Together,
they can have a much better
chance of getting therapies
through to the clinic.’’) When
he took up the Institute’s
reins, 95% of expenditures
were going to basic research
and 5% to product develop-
ment, whereas on the eve of
his departure, some 65%–
70% of expenditures were
allotted to translation and
clinical-trial work and only
30%–35% of expenditures to
basic research. Five clinical
trials are underway, for heart
disease, HIV, leukemia, and
solid-tumor cancer. Six other
trials are due to commence
by the year’s end.
The last of CIRM’s $3
billion is to be awarded in
2019 or 2020, according to
Don Gibbons. In the mean-time, CIRM’s future may hinge on Califor-
nia voters refunding the mega-agency in
2016 or on the development of new pub-
lic-private partnerships. In that CIRM’s
continuation effects thousands of scien-
tists, and may turn into a debate at ballot
time, Trounson has received criticism
for, shortly after leaving his post, joining
the board of StemCells Inc., the recipient
of $19 million in grant funds from the
agency, especially because conflict-of-
interest issues have buffeted CIRM in the
past (http://www.latimes.com/business/
hiltzik/la-fi-hiltzik-20140720-column.html#
page=1). Due to a review of CIRM’s prac-404 Cell Stem Cell 15, October 2, 2014 ª201tices by an Institute of Medicine panel in
2012, the only board members that now
vote on grant decisions are those with no
ties to any of the institutions or companies
applying. This summer, following a request
by Randal Mills, Trounson’s successor,
there was a review of all activities between
the agency and StemCells Inc., and no
conflicts were found.
Trounson, not one to shy away from
controversial topics, says he sees no con-
flict of interest in having joined StemCells’
board. ‘‘I took the best legal advice,
internally, on that matter, and it was very
clear that I could join the board,’’ says4 Elsevier Inc.Trounson. ‘‘I recused myself
in respect to one particular
project from the very begin-
ning’’—a CIRM-supported
project at StemCells Inc.—
‘‘just as a precaution, even
though I wasn’t in any finan-
cial or review conflict of inter-
est. I feel quite comfortable
about the decision, the
agency was well aware of my
recusals from the Chairman
down, and I know the com-
pany feels that way as well.’’
Two days before boarding a
flight that would reunite him
with his family in Australia, he
was unsparingly honest about
the regenerative medicine
field’s first tottering steps
toward the clinic. ‘‘We’re still
compiling the knowledge
about the basic biology. But
meanwhile, there’s such a
demand by people with dis-
eases, whether heart disease
or spinal cord injury, we are
compelled to try early treat-
ments using bone marrow
cells and other type cells, but
not with a good understand-
ing of what those cells can
do. So I’m doubtful we’ll get
the right outcome in many
of the first wave of clinical
trials. If we do, it would be
by good fortune or maybe
serendipity.’’ He believes a
second wave of clinical trials
will result in more effective
outcomes for patients based
on studies, like those sup-
ported by CIRM, that provide
sound data regarding a dis-ease’s mechanism of action. These
include a possible cure for genetic blood
diseases such as sickle cell disease and
b thalassemia, as well as HIV/AIDS, type
1 diabetes, a variety of cancers, spinal
cord damage, heart disease, and blind-
ness due to retinal degeneration. After
more knowledge is gained, a third wave
will produce ‘‘a more profound curing of
disease.’’
Filling in the knowledge gaps ‘‘will be a
30, 40, or 50 year evolvement.’’ What’s
missing, he says, is an understanding of
the cell within ‘‘the magnitude of an envi-
ronment,’’ and not only the niche it sits
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controls, and environmental clues. ‘‘Mis-
takes are being made because conclu-
sions are based on one-dimensional facts
most of the time rather than multidimen-
sional facts about how the cell works.’’
When thinking about the future, Troun-
son says that he feels ‘‘quite nervous
about what’s happening’’ in regenerative
medicine and science in general. First,
there’s the problem, especially inWestern
countries, ‘‘of too many scientists and not
enough funding.’’ He also worries about
the ‘‘commonplace’’ malaise that results
from young scientists not finding jobs
and having to look elsewhere. ‘‘In theUnited States and other countries, we’ve
been powering up our science, and get-
ting more and more students and post-
docs involved with the research, but there
hasn’t been the appropriate increase
in funding or positions in universities or
research institutes, so it’s becoming
terribly competitive for the rather small
amount of funds that do exist.’’ Funding
the pipeline for the sake of younger scien-
tists is something he cares deeply about,
all the more so as he has a son who hopes
to become a scientist but is already disil-
lusioned by the process.
Two strategies can help improve the
situation, says Trounson. Scientists needCell Stem Cell 1to do a better job of convincing commu-
nity leaders of the important role that
science plays in people’s everyday lives,
and the scientific community as a whole
needs to either restrict the number of
scientists it trains or expand the number
of positions in the private and public
sectors.
‘‘You can’t continue to produce scien-
tists and expect them to be taken up in
an economy that has limits, and if you
don’t do something about the problem,
you’ll end up with a catastrophic event,
in my mind, that will likely collapse viable
research growth’’ that is necessary for
finding cures.
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